
INDEX

A

- Abortion, 35, 36
- ACA. *See* Patient Protection and Affordable Care Act (PPACA)
- Access, to healthcare
 - equity in, 31
 - limitations to, 28
- Accountable care organizations (ACOs), 105–106, 260, 319, 320
 - financial incentives for, 106, 198
 - financial risk of, 266
 - opposition to, 319
 - provider payment strategies of, 194
- Administrative costs, in healthcare
 - of health insurance, 22, 70, 73–74
 - of Medicare, 510–511
 - US–Canada comparison of, 507, 509–511, 525n
- Admissions. *See* Hospital admissions
- Adverse selection, 82–85
 - under Affordable Care Act, 89–90
 - insurers’ protection against, 83–85
 - in long-term care insurance, 573–574, 580n
- Advertising, in healthcare
 - AMA’s restrictions on, 10, 331
 - of prescription drugs, 314, 414, 418n
- Affordable Care Act (ACA). *See* Patient Protection and Affordable Care Act (PPACA)
- AFL-CIO (American Federation of Labor-Congress of Industrial Organizations), 491–492
- Age factors. *See also* Children; Elderly population
 - in mortality causes, 37, 38
- Agency relationship, between physicians and patients, 43–49
 - imperfect agent model of, 44, 46–49
 - perfect agent model of, 43–44, 48–49
- Aid to Families with Dependent Children (AFDC), 125, 126
- Alcohol tax, 502, 504–505, 548, 550
- Ambulatory surgery centers, 238, 240
- American Academy of Family Physicians, 180
- American Association of Retired Persons (AARP), 91, 577, 592–593
- American Federation of Labor-Congress of Industrial Organizations (AFL-CIO), 491–492
- American Hospital Association (AHA), 195, 591
- American Medical Association (AMA)
 - Affordable Care Act endorsement from, 589–593
 - antitrust lawsuits against, 10, 331
 - Current Procedural Terminology (CPT) trademark monopoly of, 590
 - position on managed care, 315
 - position on Medicare, 491, 492, 496n
 - survey of time requirements for medical procedures, 156–157, 288–289
 - survey on physician practice settings, 186–187, 188
- Antitrust laws, 247
 - applied to nurses’ wages, 386
 - effect on medical marketplace, 10–11
 - purpose of, 333
- Antitrust lawsuits
 - against American Medical Association, 10, 331
 - against hospital mergers, 253, 333
- Any willing provider (AWP) laws, 315, 334, 557
- Automobile industry
 - employee healthcare costs of, 359, 368n–369n
 - labor costs of, 361
 - retiree health insurance coverage in, 364–365
 - United Auto Workers (UAW), 364–365, 591–592

B

- Baby boom generation, 113–114, 155, 156, 257, 258, 565, 575
- Balance-billing payment method, 145, 152
- Balanced Budget Act of 1997, 127, 150
- Baucus, Max, 592
- Biologics. *See* Biotechnology drugs
- Biotechnology companies, 458–459, 460
- Biotechnology drugs, 409–410, 460–461
- Block grants, 137–139

- Blue Cross/Blue Shield, 44
 - community rating-based premiums of, 87
 - hospitals' relationships with, 277–278
 - as model for Medicare, 111
 - in noncompetitive markets, 596–597
 - underestimation of claims experience by, 82
- Brown, Scott, 599
- Bundled payment system. *See* Episode-based payment system
- C**
- “Cadillac” health insurance plans, 73–74, 592
- California
 - cancer survival rates in, 508
 - charity care in, 231–232
 - disciplinary actions against physicians in, 377–378
 - health insurance premiums in, 309
 - hospital price competition in, 245–246
 - hospital utilization rates in, 308, 310
 - managed care in, 304, 306
 - Medicaid program in, 126–127
 - medical groups in, 189
 - Medicare physician payment rates in, 148, 149
- California Nurses Association, 393
- Canada
 - as percentage of worldwide pharmaceutical market, 443
 - cost-containment methods of, 507–509, 520, 522–523
 - global budgets of, 296
 - healthcare per capita costs in, 514–520
 - healthcare rationing in, 54, 518
 - as model for the United States, 522–524, 545
 - overview of, 507, 551
 - resource allocation in, 546–547
 - single-payer healthcare system of, 507–527
- Cancer survival rates, 508, 509
- Capital, labor costs–related loss of, 360, 361
- Capital investments, effect of price controls on, 290
- Capitation payment system, 22
 - advantages of, 265
 - comparison with fee-for-service payment system, 264–266
 - definition of, 170, 264, 265
 - of managed care, 303
 - of medical groups, 189, 191–192
 - of Medicare, 264
 - of Medicare Advantage, 110
- Carter, Jimmy, 8
- Case management, 11, 21, 136
- Catastrophic coverage, 21, 66, 67, 68, 501, 504, 563n
 - cost-shifting effect of, 553
 - premiums of, 555
- Celebrex, price of, 439
- Centers of excellence, 244, 338
- Certificate-of-need (CON) laws, 238, 243, 298n, 334
- Charity care, 231–232, 233–234
 - pure, 232
- Children
 - health insurance coverage for, 90
 - insured, 551
 - Medicaid coverage for, 125, 126, 127, 128–129, 137, 139
 - State Children's Health Insurance Program (SCHIP), 127–128
 - uninsured, 530
- Children's Health Insurance Program (CHIP), 128, 530, 552
- Chronic illness, managed care for, 316
- Chrysler, 364–365
- Claims experience, 80, 81–82
 - adverse selection in, 82–85
 - underestimation of, 82
- Clean Air Act, 504
- Clinical decision support systems, 179
- Clinical trials, 423, 459
- Clinton, Bill, 466, 529, 596, 598
- Clinton Administration, 540
- “Code creep,” 153, 291
- Coinsurance, definition of, 66
- Colorado, disciplinary actions against physicians in, 377–378
- Community benefits, 232
- Community Living Assistance Services and Supports (CLASS) Act, 545, 576–577
- Community rating, 334
 - under Affordable Care Act, 91–93, 246
 - versus* experience rating, 87–88
- Comparative effectiveness research (CER), 345–358
 - accuracy and timeliness of, 348–349
 - definition of, 345
 - government support for, 345–347
 - uses of, 347–351
- Competition. *See also* Antitrust laws
 - among health maintenance organizations, 11
 - among hospitals, 237–249
 - nonprice competition, 237–240
 - price competition, 240–247
 - among Medicare plans, 117–118
- Competitive markets
 - consumers' access to information in, 332
 - differentiated from medical care markets, 327–329, 340
 - of health plans, 330–331

- Competitiveness, of the United States
 effect of federal deficit on, 366
 effect of healthcare costs on, 359–370
 in automobile industry, 359, 361,
 364–365, 368n–369n
- Concentrated interests, in Affordable Care Act, 588–595, 599, 604
- Concierge medicine, 155–156, 170
 in Canada, 521
- Consumer-driven healthcare (CDHC) plans, 12, 317–318, 320
- Consumer price index (CPI), 26, 27, 172, 248n
- Consumers, healthcare decision making by, 546–547
- Consumer sovereignty concept, of national health expenditures, 19–21, 29
- Consumption efficiency
 of employer-mandated health insurance, 553
 of health savings accounts, 556
 of refundable tax credits system, 555
 of single-payer healthcare systems, 551
- Consumption efficiency, of national health plans, 546–550, 560
- Conventional health insurance. *See* Indemnity health insurance
- Copayments
 in consumer-driven healthcare, 12
 definition of, 66
 low, 39
 purpose of, 75n
- Cost(s)
 administrative
 of health insurance, 22, 70, 73–74
 US–Canada comparison of, 507, 509–511, 525n
 diffuse, 489–490, 493–494, 495
- Cost–benefit approach. *See also* External costs and benefits
 of government-funded healthcare, 20–21
 of redistributive programs, 486–487
- Cost-containment methods
 of Affordable Care Act, 12–13
 of Canadian healthcare system, 507–509, 520, 522–523
 in fee-for-service payment systems, 48
 incentives for, 22
 in managed care, 4, 26, 60–61, 251, 303, 309, 314, 315–316
 price incentives–based, 15
 in the private sector, 10
 public policy approaches to, 26–29
 during 2000s, 12–13
 during 1980s, 8–11
 during 1990s, 11–12
- Cost-effectiveness analysis, 351–352, 354
- Cost per life saved, 34, 40
 neonatal, 36
- Cost sharing
 definition of, 66
 in prescription drug coverage, 406
- Cost shifting, 271–285
 catastrophic illness-related, 553
 conditions for, 279–281
 to employees, 361
 by hospitals, 229
 under individual mandate, 558
 overview of, 282–283
 payment-to-cost ratios in, 271, 272
 for profit maximization, 273–277
- Council on Graduate Medical Education (COGME), 163, 164
- Crandall, Robert, 540
- Creative destruction, 339
- Crowd-out, 128, 574
- Current Procedural Terminology (CPT)
 coding, 590
- D**
- Daschle, Tom, 347, 595
- “Death panels,” 347
- Decision making
 about healthcare utilization, 56, 58
 about health insurance purchases, 67–68
 about national health expenditures, 15–16
 by healthcare consumers, 546–547
 in medical groups, 192
- Deductibles
 in consumer-driven healthcare, 12
 definition of, 65–66
 effect on premiums, 66, 67
 in employer-paid health insurance, 73–74
 of high-deductible plans, 12–13
 low, 39
 as moral hazard control method, 60
- Defensive medicine, costs of, 209, 212–213
- Deficit financing, of redistributive health programs, 549, 550
- Defined-benefit programs, Medicare as, 141
- Defined-contribution programs, Medicare as, 117–118
- Demand-side market failures, in medical care markets, 330–333
- Demand strategies, for reduction of physician shortage, 177–178
- Democratic Party, 588–589, 595, 596
- Dental care, health insurance coverage for, 69–70
- Diagnosis-related groups (DRGs)–based
 reimbursement, 9, 10, 21, 111, 240, 251, 252, 260, 291
- Dirksen, Everitt, 489
- Disabled persons
 Medicaid coverage for, 125, 126, 128–129, 137
 Medicare coverage for, 99, 100

- Discounts, on hospital charges, 261–262
- Discretionary use, of healthcare services, 54–56
- Disease management, 12, 303, 315–316
- Drug Competition and Patent Term Restoration Act, 424
- Drugs
 generic. *See* Generic drugs
 prescription. *See* Prescription drugs
- E**
- Economic efficiency, in healthcare, 486, 487
 of healthcare provision, 21–22, 29
 of healthcare utilization, 22–24
 of national health expenditures, 21–24
- Economic theory of regulation, 488–495
 concentrated interests concept of, 489–492
 diffuse costs concept, 489–490, 493–494, 495
- Economic theory of regulation theory, of health policy, 488–495
- Economies of scale, in medical practice, 190–191, 192–193
- Economy, effect of healthcare costs on, 365–367
- Effectiveness, of healthcare, assessment of.
 See Comparative effectiveness research (CER)
- Efficiency, of healthcare services, 31–32. *See also* Consumption efficiency; Production efficiency
- 80/20 insurance plans, 66
- Elderly population
 as healthcare consumers, 6
 healthcare costs of, 114, 308
 healthcare expenditures for, 31, 40, 575
 as healthcare reform stakeholders, 584, 588
 increase in, 404, 575
 projected, 99, 113–114, 565
 opposition to healthcare reform, 597–598, 599–600
 political power of, 40, 586, 588
 prescription drug use, 404
- Emergency department care
 as hospital revenue source, 268n
 Medicaid beneficiaries' use of, 134, 136, 138
 uninsured populations use of, 271
- Employees
 fringe benefits of, 360
 healthcare costs of, 359–364
- Employer-mandated national health insurance, 13, 15, 529–543, 593
 consequences of, 533–537
 definition of, 552
 effect on wages, 552
 “play-or-pay” employer tax penalty of, 529, 534, 535–536, 542n
 political support and opposition to, 539–540
 tax subsidies for, 533–534
 as unemployment cause, 535, 542n
- Employer-paid health insurance
 under Affordable Care Act, 13, 15
 comparison with health insurance exchanges, 556–557
 coverage for retirees, 25–26
 health plan choices in, 330–331
 managed care plans, 316
 as percentage of total health insurance market, 79
 premiums of, 11, 25, 308, 309
 determination of, 80–82
 payment-to-cost ratios of, 271
 price sensitivity of, 307
 retiree coverage of, 364–365
 during 1980s, 10
 tax-exempt status of, 6, 23, 79–80, 330, 547
 advantages of, 68–70, 74–75, 79–80
 consequences of, 70–73, 75
 discontinuation of, 554
 limitations to, 73–74, 75
- Employers
 concentrated interest in healthcare reform, 593–594
 concerns about healthcare expenses, 25–26
- End-of-life care, expenditures for, 39–40
- Episode-based payment system, 22, 157–158, 194, 198, 260–261, 264, 265
 bundled payments, 105
- Europe, prescription drug prices in, 443, 444–445
- Evidence-based medicine, 12, 316, 335
- Expenditures, as government policy instrument, 486, 487, 495
- Experience rating, *versus* community rating, 87–88
- External costs and benefits, in resource allocation, 488, 497–505
 government policies regarding, 501–504, 505
 inframarginal, 502–503
- F**
- Family planning programs, 35, 36
- Federal deficit, 114, 549
 effect on US competitiveness, 366
 financing of, 366–367
 healthcare expenditures-related, 24–25
 Medicaid-related, 15, 102, 134, 141, 366, 601

- Medicare-related, 146, 160n, 366, 552, 601
 non-healthcare-related causes of, 366
- Federal Employees Health Benefits, 118
- Federal government
 healthcare expenditures of, 24–25
 as source of medical expenses, 1, 2
- Federal Medical Assistance Percentage, 135
- Federal poverty level (FPL)
 as Medicaid eligibility determinant, 12, 24, 126, 128, 130, 132–133, 135, 139, 155, 530, 538, 584
 relationship to health insurance
 exchanges' premiums, 536, 537, 538
- Federal Trade Commission, 230, 237, 243, 253, 262, 331, 333
- Fee-for-service payment systems, 7, 43
 comparison with capitation payments, 264–266
 cost-containment methods in, 48, 50–51
 decreased use of, 194
 disadvantages of, 197–198, 264–265, 266
 effect on healthcare quality, 178, 294
 effect on hospital revenue, 265, 267
 health insurance premiums under, 47–48
 of health maintenance organizations, 7
 of managed care, 7, 304
 of Medicaid, 134
 of Medicare, 102–103, 105
- Financial Accounting Standards Board, 25, 364
- “Flat-of-the-curve medicine,” 60
- Florida, charity care in, 232
- Food, Drug, and Cosmetic Act of 1938, 422
 1962 amendments to, 422–423
- Food and Drug Administration (FDA), prescription drug approval and regulation
 activities of, 421, 422, 423, 424
 accelerated process of, 425, 426
 adverse consequences of, 425, 427–435
 time required for, 425, 426, 427–430
 Type I and Type II errors in, 429, 430
- Ford Motor Company, 364–365, 368n–369n
- For-profit hospitals
 comparison with nonprofit hospitals, 225, 227
 mergers of, 229–230
- Frank, Barney, 594
- Fraser Institute, 518–519
- Fringe benefits, 360
- Fuchs, Victor, 44
- G**
- “Gaming the system,” 294–295
- Gatekeeper model, of managed care, 136, 188–189, 191, 302, 392
- Geisinger Health System, 261
- Gender rating, of health insurance premiums, 92–93
- General Motors (GM), 359, 364–365
- Generic drug manufacturers, 455
- Generic drugs, 58–59, 406, 457
 Food and Drug Administration regulation of, 424
 market share of, 424–425
 prices of, 407, 409, 441–442
- Georgia, charity care in, 232
- Gilmour, Allan, 368n–369n
- Global budgets, 293, 295–296
 in Canada, 293
 definition of, 287, 295, 296
 in single-payer healthcare systems, 293, 551
- GM (General Motors), 359, 364–365
- Government, role in healthcare. *See* Health policies
- Grayson, C. Jackson, 295
- Great Recession (2008), 4, 12–13, 26, 28, 253, 284n, 391
- Gross domestic product (GDP), 150–151, 575
 healthcare expenditures as percentage of, 1–2, 4–5, 19, 296, 366, 367
 in Canada, 507, 511, 513
 out-of-pocket expenditures, 1–2
 relationship to Medicare growth rate, 259
 as sustained growth rate component, 292
- Group practice. *See* Medical groups
- Group purchasing organizations (GPOs), 469
- H**
- Hatch-Waxman Act, 424
- Health
 definition of, 32
 determinants of, 32
 measures of, 32
- Healthcare, low-benefit, 44
- Healthcare costs
 age-related differences in, 114
 effect on private savings, 366–367
 effect on US economy, 365–367
 effect on US industrial competitiveness, 359–370
 in automobile industry, 359, 361, 364–365, 368n–360n
 employees' share of, 359–364
 government response to, 8–13
 1980s, 8–11
 1990s, 11–12
 2000s, 12–13
 increase in
 elderly population-related, 308

- employer-paid insurance-related, 71–72
 - medical technology-related, 308, 311
- labor unions' position on, 362, 364
- per capita, US–Canada comparison of, 511–513, 514–521
- productivity-based decrease in, 288–289
- regulatory approaches to, 328–329
- Healthcare expenditures
 - age-related differences in, 91
 - appropriate amount of, 19–30
 - consumer sovereignty concept of, 19–21, 29
 - economic efficiency concept of, 21–24
 - benefits of, 19
 - decision making about, 15–16
 - effect of health insurance on, 39
 - effect on health status, 31–42
 - cost-effectiveness of, 35–37, 39, 40
 - health production function of, 33–34
 - lifestyle behaviors *versus*, 36–37
 - marginal effects of, 37–39, 40
 - over time, 37–39
 - federal and state percentages of, 99
 - government and employer concerns about, 24–26
 - increase in, 1–18, 2–3
 - appropriate rate of, 547, 561–562
 - factors affecting, 5–7, 14–15
 - limitations to, 26–29. *See also* Cost-containment methods
 - projected, 5
 - per capita, 4
 - as percentage of gross domestic product, 2, 4–5, 19
 - by percentage of population, 86
 - post-Medicaid and Medicare, 2–14
 - prior to Medicaid and Medicare, 1–2
 - sources of, 5
- Healthcare providers. *See also* Nurses; Registered nurses; Physician(s)
 - consolidation of, 333. *See also* Mergers
- Healthcare reform, 31. *See also* Patient Protection and Affordable Care Act (PPACA)
 - American Medical Association's positions on, 589–593
 - elderly population's opposition to, 597–598, 599–600
 - goals of, 583–584
 - ideological/political differences regarding, 584–585, 595–596, 598
 - legislative process of, 595–600
 - middle class's opposition to, 597–598, 599–600
- Healthcare system
 - free, 20
 - performance criteria for, 325–327
- Healthcare utilization
 - consumer decision making about, 56
 - economic efficiency of, 22–24
 - effect of out-of-pocket expenditures on, 22–23
 - by the elderly population, 6
 - inefficiency in, 22–24
 - price sensitivity of, 58–59
- Health insurance. *See also* Copayments; Deductibles; Premiums
 - administrative costs of, 22, 70, 73–74
 - cancellation of, under Affordable Care Act, 603
 - child-only coverage, 90
 - effect on demand for healthcare, 330
 - effect on healthcare expenditures, 39
 - loading charges on, 80–81, 85
 - medical loss ratio of, 67, 80, 90–91
 - moral hazard of, 59–61, 328
 - purpose of, 65
 - sources of, 79
 - terminology of, 65–67
 - value-based, 75n
- Health insurance benefits, as source of medical expenses, 1
- Health insurance companies
 - concentrated interest in Affordable Care Act, 594–595
 - price competition among, 21
- Health insurance exchanges (HIEs), 13, 88, 89
 - Bronze plans of, 537–538
 - definition of, 80
 - as employer-provided health insurance alternative, 535–537, 556–557
 - Gold plans of, 537–538
 - Platinum plans of, 537–538
 - premiums of, 89, 93, 538, 588
 - age-rated, 538–539
 - provider networks of, 246, 318–319
 - Silver plans of, 537–538
 - state's refusal to participate in, 557
 - subsidies for, 5, 15, 80, 318, 536, 538, 539
- Health insurance plans, competition among, 330–331
- Health Maintenance Organization (HMO) Act of 1973, 8–9
- Health maintenance organizations (HMOs)
 - backlash against, 11–12
 - capitation payment system of, 9, 493
 - cost-containment methods of, 170
 - competition among, 11
 - co-premium price sensitivity of, 59
 - cost savings of, 303
 - drug price discounts to, 469
 - fee-for-service payment system of, 7
 - government restrictions on, 7, 8–9
 - growth in, 9
 - healthcare services rationing by, 60–61
 - of hospital systems, 266

- market share of, 305
- medical groups as response to, 188–189
- medical groups associated with, 191–192
- Medicare, 9. *See also* Medicare Advantage plans
- patient satisfaction with, 311–312
- physician–patient agency relationship in, 48–49
- point-of-service plans, 304, 305
- provider networks/panels of, 188, 303
- underservicing of patients by, 49–50
- Health policies, 32, 485–496
 - economic theory of regulation–based, 488–495
 - public-interest theory–based, 486–488, 494, 495
- Health production function, 39
- Health savings accounts (HSAs), 317–318, 339, 555–556
- Health status
 - effect of healthcare expenditures on, 31–42
 - cost-effectiveness of, 35–37, 39, 40
 - health production function of, 32–34
 - lifestyle behaviors *versus*, 36–37
 - marginal effects of, 37–39, 40
 - of Medicaid beneficiaries, 133–134, 139
 - over time, 37–39
- Heart disease, mortality rate from, 36–37
- High-deductible health insurance plans, 263, 553
 - combined with health savings accounts, 339, 555–556
 - implication for retail medical clinics, 180
- High-risk patients, risk-adjusted premiums for, 86
- Home health care, 111
 - cost of, 568, 569–570, 571
 - Medicare coverage for, 111, 571
- Hospital(s). *See also* Nonprofit hospitals; Profit hospitals
 - closures of, 246, 248n
 - competition among, 237–249
 - nonprice competition, 237–240
 - price competition, 240–247
 - effect of cost-containment policies on, 11
 - endowment revenue of, 284n
 - excess capacity of, 252
 - expenditures for, 251
 - future role of, 251–270
 - government regulation of, 238, 240
 - length of stay in, 10, 240, 252
 - US–Canada comparison of, 513–514
 - Medicare reimbursement of, *See* Medicare reimbursement
 - mergers of, 12, 237, 243, 252–253, 268n, 269n, 314
 - antitrust lawsuits against, 253, 333
 - effect on hospital prices, 262–263
 - effect on hospitals’ market power, 281–282
 - effect on price competition, 245–246
 - of for-profit hospitals, 229–230
 - of nonprofit hospitals, 229–230
 - occupancy rates of, 11, 240, 252
 - physician practices purchased by, 193–194, 195–196, 252
 - price discounts from, 240, 242, 245, 261–262
 - profitability of, 252, 253
 - profit margins of, 253, 254
 - revenue (payment sources) of, 257–262
 - under Affordable Care Act, 257–261, 263
 - effect of fee-for-service payments on, 265, 267
 - private payers, 259, 261–262
 - public payers, 258–261
 - strategies for increasing, 265–266, 267
 - risk-sharing pools of, 190
 - specialist-owned, 195
 - utilization of
 - under Affordable Care Act, 257–262
 - by private sector, 258
 - by public sector, 257–258
 - rates of, 308, 310
 - Hospital admissions
 - effect of managed care on, 308
 - by type of hospital, 226
 - Hospital expenditures
 - as percentage of total healthcare expenditures, 251
 - price controls on, 264
 - rate of increase in, 253, 255
 - Hospital prices (charges)
 - discounts on, 240, 242, 245, 261–262
 - effect of mergers on, 262–263
 - labor costs–related increase in, 256
 - Hospital services, price sensitivity of, 58
 - Hsiao, William, 149
 - Humana, class-action lawsuit against, 315

I

 - Immigration Nursing Relief Act, 389–390
 - Immunization, external costs and benefits of, 500–501
 - Imperfect agents, physicians as, 44, 46–47
 - Income
 - effect of federal deficit on, 367
 - of physicians
 - in Canada, 507
 - in medical groups, 192
 - as rate of return on medical education, 166–167, 168, 174–175
 - supplier-induced demand model of, 44–49
 - target income theory of, 46

relationship to healthcare spending, 54–56

Income-defined programs, Medicare as, 119

Income-related tax credits, for healthcare coverage

- advantages of, 558
- health insurance exchanges–related, 556–557
- health savings accounts–related, 555–556
- refundable tax credits, 553–555, 560, 595–596

Income tax

- healthcare expenditures–related increase in, 24
- marginal rates of, 69
- as national health insurance funding source, 548–549, 550

Indemnity health insurance, 60

- cost of, 301–302
- definition of, 65
- as 80/20 plans, 66
- market share of, 304, 305
- price–quantity relationship of, 277–278

Independent Payment Advisory Board (IPAB), 106, 292

Independent practice associations (IPAs), 185–186

Indiana, charity care in, 232

Individual health insurance

- under Affordable Care Act, 88–94
- as percentage of total health insurance market, 79

Individual mandate, 558–559

- as component of universal coverage, 553
- cost shifting under, 558
- penalty for noncompliance with, 89, 563n
- with refundable tax credits, 555

Inefficiency

- in healthcare provision, 21–22
- in healthcare utilization, 22–24, 26, 50

Infant mortality rate, 508

Inflation, 6, 26, 27, 28, 171, 172

Integrated delivery systems (IDSs), 339

J

Japan, 294, 298n

“Job lock,” 85

Johnson, Lyndon B., 492

Jungle, The (Sinclair Lewis), 422

K

Kefauver, Estes, 422

Kennedy, Edward M., 599

Kidney transplantation, 473–474, 476

- dialysis *versus*, 473, 478, 482n
- living donors for, 478–480, 483n
- racial factors in, 480–481

L

Labor costs

- fringe benefits component of, 360
- wages component of, 360

Labor market, competitiveness, 359, 365

Labor unions, 25, 491–492

- concentrated interest in healthcare reform, 491–492, 591–592
- control over labor costs, 362
- opposition to Affordable Care Act, 603–604, 605
- position on healthcare costs, 362, 364
- support for Affordable Care Act, 591

Law of demand, 330

Legislative process, of healthcare reform, 595–600

Liaison Committee on Medical Education (LCME), 376, 378

Licensure, of physicians, 334, 377–379

Life expectancy, US–Canada comparison of, 508

Lifestyle behavior, effect on health status, 37, 38, 40

Loading charges, 80, 81, 85

- on long-term care insurance, 573

Long-term care, 565–582

- financing sources for, 565–582
- current state of, 568–571
- government subsidies, 571, 575, 578, 579
- Medicaid, 569–571, 578
- Medicare, 568, 569
- out-of-pocket, 569
- overview of, 565–568

Long-term care insurance, 571–575

- adverse selection in, 573–574, 580n
- demand for

 - limiting factors in, 571–575, 578
 - stimulation of, 576–577, 580n

- federal programs for, 576–577
- loading charges on, 573
- premiums of, 572, 573–574, 580n

M

Malpractice insurance premiums

- effect of damage caps on, 213
- percentage paid for malpractice claims, 210
- reasons for increase in, 203–207

Malpractice system, 203–223

- attorneys’ contingency fees in, 214, 590
- damage awards in, 206, 220n

 - caps to, 213, 590
 - collateral offset rule for, 214

- defense of, 212–213
- as medical negligence deterrent, 210–211, 218, 220
- no-fault, 215–216

- number of claims filed, 204–205, 209–210, 211
- objectives of, 207, 209–211
- overview of, 218, 220
- proposed changes in, 213–220
 - disclosure, apology, and offer, 217–218
 - enterprise liability, 216–217
 - evidence-based guidelines, 215
 - joint and several liability, 214, 216–217
 - special health courts, 214–215
 - tort reform, 590
- tort law as basis for, 204, 207, 209, 215, 218, 590
- victim compensation under, 209–210
- Managed care. *See also* Health maintenance organizations (HMOs); Preferred provider organizations (PPOs)
 - under Affordable Care Act, 318–319, 320
 - backlash against, 26, 253, 314–315, 329
 - biased selection in, 307
 - capitation payment system of, 303, 304
 - competitive effect of, 307–308
 - consumer-driven plans of, 317–318, 320
 - cost-containment methods of, 4, 26, 60–61, 251, 303, 314, 315–316, 329
 - definition of, 302–303
 - development of, 301–321
 - effect on hospital length of stay, 513–514
 - effect on hospital market competitiveness, 240, 245–246, 247
 - evolution of, 313–315
 - fee-for-service payment system of, 304
 - first-generation, 302–303
 - gatekeeper model of, 136, 188–189, 191, 302
 - government regulation of, 314–315
 - healthcare quality in, 312
 - healthcare rationing in, 60–61
 - health plan competition in, 330–331
 - increase in, 11
 - low-income individuals' participation in, 560–561
 - market share of, 304, 305
 - Medicaid plans, 136–137, 140, 141, 306
 - medical technology use in, 308, 311
 - overview of, 329
 - patient satisfaction with, 311–312
 - pay-for-performance payment system of, 317
 - performance of, 305–307
 - premiums of, 303, 305, 306, 307–308
 - price competition in, 188, 329
 - provider networks of, 253, 303–304, 307, 318
 - any-willing-provider laws regarding, 315, 334, 557
 - provider payment methods of, 304
 - report cards of, 12, 303, 316
 - risk-shifting practice of, 303
 - during 1990s, 313–314
 - second-generation, 303
 - types of plans offered by, 303–305
- Managed care organizations (MCOs)
 - as medical school owners, 376
 - restrictions on, 12
- Marginal benefit curve, 56–58
- Market competition. *See also* Competitive markets
 - partial, 329
 - relationship to consumer sovereignty, 20
- Markets, external costs and benefits of, 497–505
- Massachusetts, disciplinary actions against physicians in, 378
- Medi-Cal, 126–127
- Medicaid, 104, 125–144
 - block grants to, 137–139
 - choice of providers under, 7
 - closed provider panels of, 9
 - definition of, 2, 125
 - drug formularies of, 469
 - effect of physician shortage on, 169, 170, 171
 - elderly population covered by, 125, 126–127, 128–129, 137
 - eligibility for, 12, 125–127, 128. *See also* Medicaid, expansion under Affordable Care Act
 - assets limitation requirement, 126–127, 142n, 570–571, 573, 577
 - notch effect on, 133
 - states' policies for, 139, 258
 - variability in, 133, 139, 140, 584
 - enactment of, 99
 - enrollment in, 125–126, 128–130
 - expansion under Affordable Care Act, 5, 13, 125, 134, 257, 551
 - children's coverage under, 128
 - effect on federal deficit, 141
 - government subsidies for, 24
 - hospital revenue from, 263
 - overview of, 130–132
 - states' responses to, 530, 552
 - expenditures, 128–130
 - for beneficiary groups, 128–130
 - for elderly and disabled populations, 575
 - for hospitals, 238
 - states' attempts to control, 134, 135–136, 137–139, 142n, 539
 - for types of services, 130, 132
 - financing sources for, 2, 107, 130, 134, 550
 - Federal Medical Assistance Percentage of, 135
 - middle class as, 492–493

N

- National Bipartisan Commission on the Future of Medicare, 120
- National Commission on Physician Payment Reform, 158
- National Foundation of Independent Business (NFIB), 593–594
- National health expenditures. *See* Healthcare expenditures
- National health insurance, 545–564. *See also* Healthcare reform; Patient Protection and Affordable Care Act (PPACA)
- criteria for, 546–550
 - consumption efficiency of, 546–547, 560
 - equitable redistribution of, 547–550, 560
 - production efficiency of, 546, 560
 - proposals for, 550–562
 - elimination of state mandates, 557–558
 - employer-mandated health insurance, 552–553, 559
 - expansion of public programs, 551–552
 - health insurance exchanges, 556–557
 - health saving accounts, 555–556
 - income-tax credits, 553, 558–559
 - individual mandate, 553, 559
 - refundable tax credits, 553–555, 557
 - single-payer system, 550–551, 559, 560–562
- National Institute for Health and Clinical Excellence (NICE), 354–356
- National Organ Transplant Act, 475
- Nebraska, Medicaid program in, 599
- Neonatal intensive care units (NICUs), 32–33, 35, 36
- Neonatal mortality rate, 35–36
- New York
 - disciplinary actions against physicians in, 377–378
 - hospital utilization rates in, 308, 310
- Nixon, Richard M., 8, 387, 529
- Nonprofit hospitals, 225–236
 - charity care provided by, 231–232, 233–234
 - comparison with for-profit hospitals, 225, 227
 - definition of, 225
 - history of, 225
 - performance comparison with for-profit hospitals, 228–234
 - healthcare quality, 230–231
 - pricing practices, 229–230
 - rationale for, 227–228
 - tax-exempt status of, 231, 232–233
- Northwestern Healthcare, 230
- Notch effect, in Medicaid eligibility, 133
- Nurse practitioners, 179, 180, 182n
- Nurses. *See also* Registered nurses
 - wages of, 289, 359
- Nurse Training Act, 394. *See also* Nursing education; Nursing schools
- Nursing education/nursing schools, 387, 388, 389, 390
 - federal subsidies for, 394–395
- Nursing home care. *See also* Long-term care (LTC)
 - cost of, 568
 - Medicaid coverage for, 126–127, 137, 141
- Nursing Shortage Reduction and Education Extension Act, 389–390

O

- Obama, Barack, 588–589
 - on Affordable Care Act, 13, 587
 - on single-payer healthcare system, 594
- Obama Administration, Affordable Care Act enactment under, 271, 529, 540, 545, 583, 587, 588–589, 595, 598–602
- Ohio, disciplinary actions against physicians in, 377–378
- Older adults. *See also* Elderly population
 - health insurance premiums for, 91–92
- Oregon
 - healthcare rationing in, 54
 - Medicaid program in, 133–134
- Organ transplantation, 473–484
 - proposals for financial compensation for donors, 477–479
 - opposition to, 479–480, 481
 - sources of organs for, 473, 475–476
- Orphan drugs, 433
- Out-of-pocket costs
 - under the Affordable Care Act, 73–74
 - effective price of, 179–180
 - effect on demand for healthcare, 330
 - effect on healthcare utilization, 22–23
 - effect on price sensitivity, 188
 - for hospital costs, 237
 - for long-term care, 569
 - low, 39
 - marginal benefit curve of, 57
 - of Medicare patients, 8, 104, 107, 588
 - moral hazard of, 59–61
 - as percentage of total healthcare expenditures, 6, 328
 - for prescription drugs, 404, 405, 406, 407, 408, 414–415
 - under Medicare Part D, 588
 - under price controls, 290
 - prior to Medicaid and Medicare, 1–2
 - reduction in, 6, 7
 - stop loss limits on, 60, 66
 - wait time–related, 58, 293, 297–298
- Outpatient care
 - growth of, 252
 - increase in, 263, 264

P

- Patient Protection and Affordable Care Act (PPACA)
- adverse consequences of, 605
 - adverse selection under, 89–90
 - benefits' phase-in times of, 545
 - “Cadillac” health insurance tax of, 73–74, 592
 - Community Living Assistance Services and Supports (CLASS) Act and, 545, 576–577
 - community rating requirement of, 246
 - comparative efficiency research provision of, 345
 - cost-containment policies of, 12–13
 - effect on demand for healthcare, 15
 - effect on federal healthcare expenditures, 24
 - employer-mandated health insurance provision. *See* Employer-mandated national health insurance
 - enactment of, 545, 583, 598–600
 - Essential Health Benefits mandated by, 552–553, 563n
 - evaluation criteria for, 12–13
 - future of, 605
 - groups with concentrated interests in, 588–595, 604
 - healthcare financing under, 550
 - healthcare services' efficiency under, 15
 - health insurance benefits expansion under, 92
 - health insurance exchanges provision of. *See* Health insurance exchanges (HIEs)
 - health insurance premiums under, 92–93
 - hospital utilization under, 257–261
 - implementation of, 603–604
 - Independent Payment Advisory Boards of, 106, 259, 264, 292, 591, 602
 - individual health insurance market under, 88–94
 - individual mandate of, 13, 85, 505–506, 533, 557
 - health insurers' support for, 594
 - penalties for noncompliance with, 13, 563n
 - managed care under, 318–319, 320
 - Medicaid expansion under, 5, 13, 125, 134, 155, 257, 551
 - children's coverage under, 128
 - effect on federal deficit, 141
 - government subsidies for, 24
 - hospital revenue from, 263
 - overview of, 130–132
 - states' responses to, 530, 532
 - medical loss ratio provision of, 91
 - Medicare payroll tax provision of, 100, 109
 - Medicare reimbursement under, 104–106, 259–260, 263–264, 292–293
 - overview of, 545, 583
 - political aspects of, 583, 584–585
 - preexisting conditions provision of, 89–90, 92–93
 - preventive services requirement of, 92
 - proposed changes to, 545
 - public option plan for, 596–597, 602
 - summary of, 611–617
 - uninsured populations' insurance coverage under, 12, 233–234
- Pay-for-performance (P4P) payment system, 12
 - definition of, 317
 - in managed care, 317
 - of medical groups, 191
- Payroll tax
 - as Medicare funding source, 8, 24, 69, 100–101, 107–108, 109, 111, 114, 117, 481, 492, 550
 - as national health insurance funding source, 548, 550
- PBMs (pharmacy benefit managers), 412, 417n, 457, 459
- Peer review, 376
- Pharmaceutical industry, 455
 - competitiveness of, 460
 - price competition in, 460
 - structure of, 456–460
 - worldwide market of, 443
- Pharmaceutical manufacturers
 - drug pricing practices of
 - cost-based, 410–411
 - demand-based, 411–412
 - for new innovative drugs, 412–414
 - in response to managed care, 414–415
 - research and development activities of
 - effect of price controls on, 464, 466–468
 - new strategies for, 458–460
 - research and development costs to, 427–428, 430–433, 434–435, 455, 456, 500
 - fixed costs, 442–443
 - variable costs, 443
 - support for Affordable Care Act from, 589
- Pharmaceutical Research and Manufacturers of America, 589
- Pharmacy benefit managers (PBMs), 412, 417n, 457, 459
- Physician(s). *See also* Primary care physicians; Specialists
 - acceptance of new Medicaid/Medicare patients, 8, 136–137, 171, 173
 - disciplinary actions against, 377–378
 - excessive provision of healthcare by, 20
 - female, practice settings of, 187

- hospital-employed, 187, 195–197, 262–263
- income of, 22, 173
- in Canada, 507
 - in medical groups, 192
 - as rate of return on medical education, 166–167, 168, 174–175
 - supplier-induced demand model of, 44–49
 - target income theory of, 46
- monitoring of, 50
- number of, 9. *See also* Physician shortage
- increase in, 44, 45
 - relationship to supplier-induced demand, 47
 - surplus of, economic definitions of, 164–167
- as patients' agents, 43–47
- supplier-induced demand for, 44–49
- Physician assistants, 179
- Physician extenders, 179
- Physician fees
- Affordable Care Act–mandated reduction in, 593
 - discounting of, 188
 - effect of Medicare price controls on, 291–292
 - effect of physician supply on, 169–170, 171
 - in managed care, 188
 - price sensitivity to, 188
 - relationship to inflation, 171, 172
- Physician groups. *See* Medical groups
- Physician–hospital relationship, 226, 266
- Physician–patient relationship, effect of cost-containment policies on, 11
- Physician practice management (PPM) companies, 193
- Physician practice patterns, 303
- monitoring of, 377–379
- Physician practices. *See also* Medical groups
- hospitals' purchase of, 193–194, 195–196
- Physician profiles, 50
- Physician Quality Reporting System, 157
- Physician requirement ratio, 164
- Physician services
- price sensitivity of, 58
 - supplier-induced demand for, 44–47
 - utilization by the elderly, 6
- Physician shortage, 15, 163–184
- economic definitions of, 164–167
 - effect on the private health insurance market, 167–169
 - effect on the public health insurance market, 169–170
 - evidence for, 164–177
 - long-term outlook for, 177–180
 - overview of, 181
 - strategies for reduction of
 - demand strategies, 177–178, 181
 - supply strategies, 178–180, 181
- Physician-to-population ratio, 44, 45, 47, 164, 493
- Point-of-service plans, 304, 305
- Pollution control, external costs and benefits of, 488, 498–500, 503–504, 505n
- Population pyramid, of the United States, 115
- Preexisting conditions, as basis for denial of health insurance, 85, 89–90, 557
- Preferred provider organizations (PPOs), 11, 48, 303–304
- adoption by non-managed care insurers, 307
 - during 1990s, 314
- Preferred-risk selection, 5–87
- Premiums
- actual, 67
 - under Affordable Care Act, 13, 92–93
 - calculation of, 80–82
 - in consumer-driven healthcare, 12
 - determinants of
 - adverse selection, 82–85
 - claims experience, 80, 81–82
 - community *versus* experience ratings, 87–88
 - preferred-risk selection, 85–87
 - effect of deductibles on, 66, 67
 - effect of state health mandates on, 557
 - in fee-for-service payment systems, 47–48
 - gender-based rating of, 92–93
 - increases in, 12–13
 - loading charges on, 67–68, 80, 81
 - of malpractice insurance
 - effect of damage caps on, 213
 - percentage paid for malpractice claims, 210
 - reasons for increase in, 203–207
 - of managed care, 303, 305, 306, 307–308, 309, 311
 - medical loss ratio of, 67, 80, 90–91
 - organ donation–related reduction in, 477–478
 - pure, 66–67, 68
 - reduction in, 76n, 320
 - regulation of, 28
 - risk-adjusted, 312, 331
- Premium support, 117–118
- Prenatal care, 36
- Prescription drug prices, 401–419. *See also* Pharmaceutical industry; Pharmaceutical manufacturers
- cross-national studies of, 439–453
 - drug therapy costs, 441–442
 - overview of, 449–450
 - price controls, 444–450
 - price index of, 442
 - public policy issues, 445–449

- reimportation of drugs, 447–449
- retail price comparisons, 440
- uniform prices, 446–447
- demand-based, 456
- of generic drugs, 407, 409, 441–442
- increase in, 407
- of new innovative drugs, 407, 409–410, 412–414, 415–416
- overview of, 415–416
- price controls on, 444–445, 462–469, 470
 - cross-national studies of, 444–450
 - price sensitivity of, 407, 414
 - pricing practices for, 410–415, 416
- Prescription drugs. *See also* Pharmaceutical industry; Pharmaceutical manufacturers
 - age-related use of, 402, 404
 - clinical trials of, 423, 459
 - copayments for, 407, 410, 414–415
 - cost sharing for, 462
 - direct-to-consumer advertising of, 314, 414, 416n
 - distribution channels for, 455
 - expenditures on, 401, 402
 - Food and Drug Administration approval and regulation of, 421, 422, 423, 424
 - accelerated process of, 425, 426
 - adverse consequences of, 425, 427–435
 - history of, 421–425
 - time required for, 425, 426, 427–430
 - Type I and Type II errors in, 429, 430
 - increase in use of, 401, 403–407
 - Medicaid coverage for, 404, 406, 408
 - Medicare coverage for. *See* Medicare Part D
 - new and innovative, 460–462
 - effect of price controls on, 464–466
 - first in class, 460, 461
 - global new chemical entities (NCEs), 460–462
 - safety and efficacy of, 421–438
 - as “orphan” drugs, 433
 - out-of-pocket expenditures for, 404, 405, 406, 407, 408, 414–415
 - patent expirations on, 456–458, 466
 - private health insurance coverage for, 404, 405, 407, 408
- Prescription Drug User Fee Act, 425
- Preventive care
 - Affordable Care Act requirements for, 92
 - physician incentives for provision of, 178
 - US–Canada comparison of, 508, 515
- Price(s), of healthcare services
 - artificially lowered, 23
 - cost-based, 56
 - effect of Medicare on, 5–6
 - effect of supply and demand on, 5–7
 - healthcare rationing based on, 53, 54–56
 - lack of information about, 331–332
 - marginal benefit curve of, 56–58
 - of nonprofit *versus* for-profit hospitals, 229–230
 - profit-maximizing, 273–277
 - relationship to total revenue, 273, 274, 275, 283n
- Price competition
 - among health insurance companies, 21
 - among hospitals, 281
 - conditions for, 10–11
 - effect of labor costs on, 360–361
 - in healthcare market, 337–338
 - in managed care, 188, 329
 - in the pharmaceutical industry, 460
 - states’ regulation of, 333–334
- Price controls, 387
 - in Canadian healthcare system, 552
 - global budgets of, 293, 295–297
 - for healthcare expenditures management, 287–299
 - actual effects of, 291–295
 - overview of, 296–297
 - theoretical basis for, 287–290
 - on Medicaid, 291, 552
 - on Medicare, 264
 - as motivation for “gaming the system,” 294–295
 - on prescription drugs, 444–445, 462–469, 464, 466–468, 470
 - cross-national studies of, 444–450
- Price discounts, from hospitals, 240, 242, 245, 261–262
- Price discrimination
 - in hospital prices, 278–279, 282–283
 - in pharmaceutical marketing, 412, 416, 417n–418n
- Price elasticity, 276
- Price fixing, 242–243
- Price incentives, as cost-containment method, 15
- Price inelasticity, 276
- Price sensitivity, 58–59, 62
 - copayment-based, 75n
 - effect on hospital prices, 277–278, 283n–284n
 - of employer-paid health insurance, 74, 307
 - in healthcare utilization, 58–59
 - of health insurance plans, 277–278
 - of Medicare patients, 177–178
 - of prescription drugs, 407, 412, 414
- Primary care physicians
 - education of, 178–179
 - gatekeeper role of, 136, 188–189, 191, 302
 - Medicaid reimbursement to, 130, 132, 136–137

- Medicare fee schedule for, 154, 155, 157
 Medicare reimbursement to, 292
 practice settings of, 186, 187
 refusal to accept Medicare patients, 292
 shortage of, 163, 176–177, 178–179
 supplier-induced demand for, 47
- Private health insurance
 administrative costs of, 22
 under Affordable Care Act, 13
 in Canada, 520, 521–522, 547
 “crowd-out” by public health insurance, 128
 growth of, 6
 mandated Essential Health Benefits coverage of, 552–553, 563n
 markets for, 79–80
 payment-to-cost ratios of, 281, 282
 as percentage of total health insurance market, 79
 premiums of, 596
 determinants of, 80–82
- Private nonprofit hospitals. *See* Nonprofit hospitals
- Private prescription drug plans, 58–59
- Private sector
 healthcare cost-containment policies in, 10
 health policy approaches of, 560, 561
- Production efficiency
 in employer-mandated health insurance, 553
 in single-payer healthcare systems, 551
- Production efficiency, of national health plans, 546, 560
- Productivity
 effect on employee compensation, 362
 of healthcare providers, 288–289
- Profit, price-based maximization of, 273–277
- Program of All-Inclusive Care for the Elderly (PACE), 578
- Property taxes, 548, 550
- Public-interest theory, of health policy, 486–488, 495
- Pure Food and Drug Act, 421–422
- Q**
- Quality, of healthcare
 effect of price controls on, 294
 in managed care, 312
 provided by medical groups, 191
- Quality-adjusted life years (QALYs), 352–356
- R**
- Rationing, of healthcare, 20
 in Canada, 54, 518
 government non-price approach in, 53–54, 61
- in managed care, 60–61
 by market-determined price, 53, 54–61
 need for, 53, 61
 under price controls, 293
- Reagan Administration, 9
- Recessions
 Great (2008), 4, 12–13, 26, 28, 253, 284n, 391
 1980s, 10
- Redistributive health programs, 486–487.
See also Medicaid; Medicare
 economic theory of regulation-based, 495
 equitable, 547–550
 financing for, 548–549
 Medicare as, 107–111, 491–492
 public-interest theory-based, 486–488, 495
 tax-based financing for, 548–549, 550
- Redistributive legislation
 purpose of, 604
 visible redistributive effects of, 491
- Reference pricing, 74, 338
- Referrals
 in managed care, 188–189, 191, 304
 wait time for, 518–520, 521
- Refundable tax credit systems, 553–555, 560, 595–596
- Registered nurses
 demand for, 256
 shortage of, 256, 383–399
 after passage of Medicare and Medicaid, 386–390
 factors affecting supply and demand, 392–394
 measurement of, 383–384
 overview of, 396–397
 prior to passage of Medicare and Medicaid, 385–386
 wages of, 256, 385–387, 389, 390, 394, 396
- Regressive tax, 548–549
- Regulation, as government policy instrument, 486
- Reinhardt, Uwe, 367–368
- Renal disease patients, Medicare coverage for, 99
- Report cards, 12, 303, 316
- Republican Party, 588, 595–596, 598, 599
- Residencies, 168–169, 179, 371
- Resource allocation
 efficiency in, 487
 external costs and benefits of, 497–505
 for health status improvement, 34
 inefficiency in, 487
- Resource-based relative value scale (RBRVS)
 fee schedule, 9–10, 147–149, 152, 153, 154, 158
- Retail medical clinics, 179–180

- Retirees, employer-paid health insurance expenditures for, 25–26, 491–492
- Retirees, funding of healthcare costs of, 364–365, 369n
- Retirement benefits, 362
- Retrospective review, 302–303
- Rhode Island, Medicaid waiver program in, 138
- Risk-sharing pools, 76n, 190
- S**
- Sales tax, 548, 550
- Savings, effect of healthcare costs on, 366–367
- Selective contracting, 302
- Self-employed individuals, healthcare costs of, 84–85
- Service benefits insurance policies, 65
- Shalala, Donna, 447
- Single-payer healthcare systems. *See also* Canada, single-payer healthcare system of; United Kingdom labor unions' support for, 591–592 Obama on, 594 overview of, 550–551 proposed adoption by United States, 550–551, 559
- “Sin” taxes, 548, 550–551
- Small business, opposition to Affordable Care Act, 593–594
- Smoking cessation programs, 34
- Social health maintenance organizations, 578
- Social Security eligibility age for, 116 payroll tax funding for, 491–492 as percentage of gross domestic product, 575
- Specialists acceptance of new Medicaid patients by, 171, 173 decreased demand for, 188–189 group practices of, 188 as hospital owners, 195 income of, 168, 176 Medicare fee schedule for, 149, 152–153 practice settings of, 186, 187 specialty board certification of, 378 surplus of, 163
- Specialties, medical education in, 168, 176
- Specialty medical groups, 185 multispecialty as accountable care organizations, 198 challenges to, 191–194, 199 hospital-owned, 196 single-specialty, 194–195
- Specter, Arlen, 588
- State Children's Health Insurance Program (SCHIP), 127–128
- State health insurance exchanges. *See* Health insurance exchanges
- State health insurance mandates, 333–334 proposed elimination of, 557–558
- State practice acts, 334
- Static shortages, 166
- Statistical deaths, 428–429, 436n–437n
- Stop loss, 60, 66
- Supplier-induced demand, 335
- Supply and demand, for healthcare services effect of Medicare on, 5–6 effect on prices, 5–7 imbalance in, 287–288 for physician services in private market, 167–169 in public market, 169–170
- Supply ratio, 164
- Supply-side failures, in medical care markets, 333–334
- Supply strategies, for reduction of physician shortage, 178–180
- Surgeons, supplier-induced demand for, 47
- Surgery, second-opinion requirements for, 48
- Sustainable growth rate (SGR), 111, 150–152, 154–155, 158–159, 160n, 296, 589–590
- T**
- Taxation as government policy instrument, 486 as national health insurance funding source, 548, 550
- Tax credits, income-related, for healthcare coverage advantages of, 558 health insurance exchanges–related, 556–557 health savings accounts–related, 555–556 refundable tax credits, 553–555, 560, 595–596
- Tax-exempt status of consumer-driven healthcare plans, 317–318 of employer-paid health insurance, 6, 23, 79–80, 330, 547 advantages of, 68–70, 74–75, 79–80 consequences of, 70–73, 75 discontinuation of, 554 limitations to, 73–74, 75 of nonprofit hospitals, 231, 232–233
- Tax penalty, individual mandate–related, 89, 563n
- Technological Change in Healthcare (TECH) Research Network, 516–517
- Technological imperative, 44
- Telehealth, 179

- Temporary Assistance to Needy Families (TANF), 126
- Texas
charity care in, 232
disciplinary actions against physicians in, 377–378
- Thalidomide, 422–423
- Tort law, 204, 207, 209, 215, 218, 590
- Trade balance, 365, 366
- Training, of health professionals, 334. *See also* Medical education; Medical schools
- Treatment effectiveness, assessment of. *See* Comparative effectiveness research (CER)
- TRICARE, 485
- Trust, in nonprofit hospitals, 227, 228
- U**
- Uncertainty, 83
- Uninsured population
under Affordable Care Act, 12, 233–234
emergency department care use by, 271
enrollment in Medicaid, 126, 134
hospital pricing practices for, 229
nonprofit hospital care for, 227
proposals for health insurance coverage for, 595–596
reasons for not having health insurance, 532–533
- Unions. *See* Labor unions
- United Auto Workers (UAW), 364–365, 591–592
- United Kingdom
healthcare rationing in, 54
hospital competition in, 248n
medical education in, 374
National Health Service of, 524
prescription drug approval rate in, 427
private health insurance in, 296
wait times for surgery in, 293
- Universal coverage, 28–29
in Canada, 509
effect of employer-mandated health insurance on, 533, 541
- Unmanaged care/health plans, 304, 311, 312
- User tax, 549, 550
- Utilization management, in preferred provider organizations, 304
- Utilization review, 8, 11, 48
components of, 302–303
effect on hospital admissions, 240
use by managed care insurers, 307
- V**
- Value, of healthcare, marginal benefit curve of, 56–58
- Value-based purchasing, 338
- Voluntary Employee Beneficiary Association, 365
- Voucher system, 139–140
- W**
- Wage controls, 387
- Wages
effect of employer-mandated health insurance on, 534, 536–537, 542n, 552
effect of healthcare costs on, 360, 361
effect of price controls on, 289–290
as labor costs component, 360
of nurses, 256, 289, 385–387, 389, 390, 394, 396
- Wait time
in Canada, 547
costs of, 58
effective price of, 179–180
effect of physician shortage on, 169, 170–171, 173, 181
out-of-pocket costs of, 58, 293, 297–298
in single-payer healthcare systems, 293, 294, 518–520, 521, 551
US–Canada comparison of, 293, 294, 518–520, 521
- Washington state, Medicaid waiver program in, 138
- Welfare reform, 126
- World War II, 53, 70
- Y**
- Young adults, health insurance coverage for, 530, 595